Results 241 to 250 of about 4,219,171 (314)

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Conflict Behaviour Frequency During Show Jumping Competitions: A Practical Study. [PDF]

open access: yesAnimals (Basel)
Nothaft IT   +4 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

open access: yesMolecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary   +1 more
wiley   +1 more source

Work-Family Conflict and Intention to Leave Among Nursing Professionals: A Cross-Sectional Study. [PDF]

open access: yesHealthcare (Basel)
Ventura-Silva JMA   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy